CA-LATTICEFLOW-AI
23.4.2024 09:01:32 CEST | Business Wire | Press release
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF).
Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and collaborating on new approaches for scalable evaluations.”
Executive Demand for Trustworthy AI
Despite the impressive accuracy of AI models demonstrated in pilots and proof-of-concept projects, building AI solutions that perform reliably on real-world data remains an immense challenge. This affects both technical teams building and delivering AI solutions as well as management teams that need to quantify risks and approve AI solutions for use in business-critical operations. As a result, 85% of the models never make it into production, and out of those that do, 91% degrade over time.
“Unfortunately, high-value AI deployments are being delayed due to developer delay, insufficient good data governance and the inability to quantify possible risks associated with the use of their AI models,” stated Randolph Kahn Esq., President of Kahn Consulting Inc. “Consortiums such as AISIC can produce detailed guidelines and best practices, and when coupled with LatticeFlow AI’s technology, this can lead to a significant reduction of the time and cost required to complete thorough risk assessments and unlock the value of AI systems.”
The U.S. AI Safety Institute Consortium
AISIC was established by the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) to contribute to the priority actions outlined in U.S. President Biden’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of AI. These include developing red-teaming guidelines, technical assessment standards, and risk management practices, among other key elements to the development of trustworthy AI and its responsible use.
LatticeFlow AI's Contributions to Making AI Safe and Trustworthy
LatticeFlow AI’s association with AISIC follows a series of contributions made by the LatticeFlow AI team towards the goals outlined by AISIC and President Biden’s Executive Order. Since 2020, LatticeFlow AI has been an invited technical contributor to key AI Safety initiatives at the International Organization for Standardization, where it has actively contributed to the working group focusing on the development and standards for Trustworthy AI. Earlier this year, LatticeFlow AI hosted renowned AI leaders at the World Economic Forum’s AI House, gathering key figures in AI, including Gary Marcus (NYU), Apostol Vassilev (NIST), Kai Zenner (European Parliament), Matthias Bossardt (KPMG), Thomas Stauner (BMW), among other industry experts, to delve into the latest AI developments and discuss responsible AI adoption.
From Standards to Practice: First AI Assessment for a Leading Swiss Bank
Moving beyond the development of AI guidelines and standards, this year, LatticeFlow AI announced the first industry-pioneering technical AI Assessment for Migros Bank, a leading Swiss Bank, demonstrating how these AI standards are used in practice to mitigate risk and ensure regulatory compliance for business-critical AI solutions. The results of this assessment, alongside a concrete blueprint to implement AI governance and technical AI assessments at enterprises and governments, were presented at a dedicated event hosted at the ETH AI Center.
LatticeFlow AI’s Commitment to the U.S. and NIST’s AI Safety Institute Consortium
With its contributions to AISIC, LatticeFlow AI will continue its commitment to helping U.S. government agencies such as the U.S. Army ensure the safety and trustworthiness of mission-critical AI systems. Last year, White House officials announced LatticeFlow AI as the first-place winner in the “red teaming” AI Privacy Prize Challenge category. Subsequently, the company announced a strategic expansion towards the US and a three-year strategic engagement with the U.S. Army to build next-generation resilient AI solutions for mission-critical defense use cases.
"Joining AISIC will allow us to accelerate and broaden our impact by aligning our efforts towards ensuring AI trust and safety with global AI leaders, enterprises, and governments," said Petar Tsankov, Co-founder and CEO of LatticeFlow AI.
Interested in learning more?
- Watch the replay of our event on AI Governance & Audits: Navigating AI Risks and Compliance.
- Visit our web page to learn how to manage your AI model risk with comprehensive technical AI assessments.
- If you are interested in conducting an AI assessment, book a meeting with a LatticeFlow AI expert.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423153331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
